PTO Form 1581 (Rev 9/2005)
`
`OMB No. 0651-0054 (Exp. 10/31/2017)
`
`Request for Extension of Time to File a Statement of Use
`(15 U.S.C. Section 1051(d))
`
`Input Field
`
`SERIAL NUMBER
`
`LAW OFFICE ASSIGNED
`
`MARK SECTION
`
`MARK
`
`STANDARD CHARACTERS
`
`USPTO-GENERATED IMAGE
`
`LITERAL ELEMENT
`
`OWNER SECTION
`
`NAME
`
`STREET
`
`CITY
`
`STATE
`
`ZIP/POSTAL CODE
`
`COUNTRY
`
`PHONE
`
`FAX
`
`EMAIL
`
`The table below presents the data as entered.
`
`Entered
`
`85350709
`
`LAW OFFICE 116
`
`BASAGLAR
`
`YES
`
`YES
`
`BASAGLAR
`
`Eli Lilly and Company
`
`Lilly Corporate Center
`
`Indianapolis
`
`Indiana
`
`46285
`
`United States
`
`317-276-9624
`
`317-276-1919
`
`trademarks@lilly.com
`
`GOODS AND/OR SERVICES SECTION
`
`INTERNATIONAL CLASS
`
`005
`
`CURRENT IDENTIFICATION
`
`Pharmaceutical preparations, namely, pharmaceutical preparations for the
`treatment of alcohol use disorders, Alzheimer's, anxiety disorders,
`atherosclerosis, autoimmune diseases and disorders, blood disorders, bone
`and skeletal diseases and disorders, cancer, cardiovascular diseases, central
`nervous system diseases and disorders, cholesterol disorders, cystic fibrosis,
`dementia, dermatological diseases and disorders, diabetes, dyslipidemia,
`endocrine diseases and disorders, gastrointestinal diseases and disorders,
`hormonal diseases and disorders, inflammation and inflammatory diseases
`and disorders, kidney diseases and disorders, liver diseases and disorders,
`metabolic diseases and disorders, migraines, muscle diseases and disorders,
`neurodegenerative diseases and disorders, neurological disorders, pain,
`pancreatic diseases and disorders, psychiatric disorders, reproductive system
`diseases and disorders, sleep disorders, urological disorders; antidepressants
`
`GOODS OR SERVICES
`
`EXTENSION SECTION
`
`EXTENSION NUMBER
`
`KEEP ALL LISTED
`
`5
`
`

`

`ONGOING EFFORT
`
`ALLOWANCE MAIL DATE
`
`STATEMENT OF USE
`
`PAYMENT SECTION
`
`NUMBER OF CLASSES
`
`SUBTOTAL AMOUNT
`
`TOTAL AMOUNT
`
`SIGNATURE SECTION
`
`SIGNATURE
`
`SIGNATORY'S NAME
`
`SIGNATORY'S POSITION
`
`DATE SIGNED
`
`SIGNATORY'S PHONE NUMBER
`
`FILING INFORMATION
`
`SUBMIT DATE
`
`TEAS STAMP
`
`product or service research or development
`
`12/27/2011
`
`NO
`
`1
`
`150
`
`150
`
`/blongbottom/
`
`Bruce W. Longbottom
`
`Assistant General Counsel
`
`05/20/2014
`
`317 651 1346
`
`Tue May 20 17:21:26 EDT 2014
`
`USPTO/ESU-XX.X.XX.XX-2014
`0520172126481717-85350709
`-5002e8253c9fac5c8f56c548
`ea3b2db1b7c4ca579dffe37f6
`0bd280d2f621-DA-4117-2014
`0519183217655332
`
`

`

`PTO Form 1581 (Rev 9/2005)
`
`OMB No. 0651-0054 (Exp. 10/31/2017)
`
`To the Commissioner for Trademarks:
`
`MARK:(cid:160)BASAGLAR
`SERIAL NUMBER:(cid:160)85350709
`
`SOU Extension Request
`(15 U.S.C. Section 1051(d))
`
`The applicant, Eli Lilly and Company, having an address of
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)Lilly Corporate Center
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)Indianapolis, Indiana 46285
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)United States
`requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. (cid:160)(cid:160) The Notice of Allowance
`mailing date was 12/27/2011.
`
`For International Class 005:
`Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's,
`anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer,
`cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases
`and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders,
`inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and
`disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases
`and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antidepressants
`
`For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection
`with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification
`mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or
`in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
`specific class.
`
`This is the fifth extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with
`each of those goods/services covered by the extension request: product or service research or development
`
`A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.
`
`Declaration
`
`STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention to use or use through the applicant's related
`company or licensee the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as
`subsequently modified; and that to the best of the signatory's knowledge and belief, no other person has the right to use the mark in commerce,
`either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other
`person, to cause confusion or mistake, or to deceive.
`
`DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under
`18 U.S.C. Section 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any
`resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief
`are believed to be true.
`
`Signature: /blongbottom/(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)Date Signed: 05/20/2014
`Signatory's Name: Bruce W. Longbottom
`Signatory's Position: Assistant General Counsel
`
`

`

`Signatory's Phone: 317 651 1346
`
`RAM Sale Number: 85350709
`RAM Accounting Date: 05/21/2014
`
`Serial Number: 85350709
`Internet Transmission Date: Tue May 20 17:21:26 EDT 2014
`TEAS Stamp: USPTO/ESU-XX.X.XX.XX-2014052017212648171
`7-85350709-5002e8253c9fac5c8f56c548ea3b2
`db1b7c4ca579dffe37f60bd280d2f621-DA-4117
`-20140519183217655332
`
`

`

`TEAS ROUTING SHEET
`
`To: INTENT TO USE UNIT
`
`Work Loc: INTENT TO USE SECTION
`
`Doc Type: Extension Request for SOU
`
`Serial Number: 85350709
`
`Mark: BASAGLAR
`
`Mail Date: 2014/05/20
`
`Examiner Number: 73703
`
`Examiner Name:
`CARROLL, DORITT
`
`L.O. Assigned: LAW OFFICE 116
`
`Special Instruction(s):
`
`Transaction
`
`Fee
`Code
`
`Transaction
`Date
`
`Fee per
`Class
`
`Total
`Number
`of Classes @
`
`Extension Request for SOU
`
`7004
`
`20140520
`
`$150
`
`1
`
`$150
`
`